NO20054951D0 - Prostaglandinanaloger som EP4-reseptorantagonister - Google Patents
Prostaglandinanaloger som EP4-reseptorantagonisterInfo
- Publication number
- NO20054951D0 NO20054951D0 NO20054951A NO20054951A NO20054951D0 NO 20054951 D0 NO20054951 D0 NO 20054951D0 NO 20054951 A NO20054951 A NO 20054951A NO 20054951 A NO20054951 A NO 20054951A NO 20054951 D0 NO20054951 D0 NO 20054951D0
- Authority
- NO
- Norway
- Prior art keywords
- receptor antagonists
- prostaglandin analogues
- prostaglandin
- analogues
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45770003P | 2003-03-26 | 2003-03-26 | |
PCT/CA2004/000471 WO2004085431A1 (en) | 2003-03-26 | 2004-03-26 | Prostaglandin analogs as ep4 receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20054951D0 true NO20054951D0 (no) | 2005-10-25 |
NO20054951L NO20054951L (no) | 2005-12-22 |
Family
ID=33098243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054951A NO20054951L (no) | 2003-03-26 | 2005-10-25 | Prostaglandinanaloger som EP4-reseptorantagonister |
Country Status (22)
Country | Link |
---|---|
US (4) | US7053085B2 (no) |
EP (1) | EP1613621B1 (no) |
JP (1) | JP4866992B2 (no) |
KR (1) | KR20060002873A (no) |
CN (1) | CN1764659A (no) |
AR (1) | AR040806A1 (no) |
AT (1) | ATE474837T1 (no) |
BR (1) | BRPI0408690A (no) |
CA (1) | CA2519938C (no) |
CL (1) | CL2004000655A1 (no) |
DE (1) | DE602004028229D1 (no) |
EC (1) | ECSP056037A (no) |
ES (1) | ES2347434T3 (no) |
HR (1) | HRP20050845A2 (no) |
IS (1) | IS7999A (no) |
MA (1) | MA27667A1 (no) |
MX (1) | MXPA05010189A (no) |
NO (1) | NO20054951L (no) |
PE (1) | PE20050522A1 (no) |
RU (1) | RU2005132930A (no) |
TW (1) | TW200427670A (no) |
WO (2) | WO2004085431A1 (no) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7053085B2 (en) * | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
CA2511255C (en) * | 2003-01-10 | 2009-04-07 | F. Hoffmann-La Roche Ag | 2-piperidone derivatives as prostaglandin agonists |
US7326716B2 (en) | 2003-06-06 | 2008-02-05 | Allergan, Inc. | Treatment of inflammatory bowel disease |
US6977260B2 (en) | 2004-01-22 | 2005-12-20 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
CA2528179C (en) * | 2003-06-06 | 2013-10-22 | Allergan, Inc. | Piperidinyl prostaglandin e analogs |
US7179820B2 (en) | 2003-06-06 | 2007-02-20 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
US7576122B2 (en) | 2003-09-02 | 2009-08-18 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
KR20060090801A (ko) | 2003-09-04 | 2006-08-16 | 머크 앤드 캄파니 인코포레이티드 | 고안압증 치료용 안용 조성물 |
JP2007504236A (ja) | 2003-09-04 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼用組成物 |
EP1771427A1 (en) | 2004-07-02 | 2007-04-11 | Allergan Inc. | Prostaglandin analogs |
JP2008507521A (ja) * | 2004-07-20 | 2008-03-13 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼科用組成物 |
US20080132543A1 (en) * | 2004-10-26 | 2008-06-05 | Wha Bin Im | Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists |
WO2006052630A1 (en) * | 2004-11-04 | 2006-05-18 | Allergan, Inc. | Therapeutic substituted piperidone compounds |
KR100890490B1 (ko) * | 2005-01-27 | 2009-03-26 | 아사히 가세이 파마 가부시키가이샤 | 헤테로 6원환 화합물 및 그의 용도 |
US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
WO2007014462A1 (en) * | 2005-08-03 | 2007-02-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
CA2616604A1 (en) * | 2005-08-03 | 2007-02-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
UY30121A1 (es) | 2006-02-03 | 2007-08-31 | Glaxo Group Ltd | Nuevos compuestos |
US7550448B2 (en) | 2006-05-24 | 2009-06-23 | Allergan, Inc. | Therapeutic compounds |
US7498447B2 (en) | 2006-05-24 | 2009-03-03 | Allergan, Inc. | Therapeutic compounds |
WO2008027340A2 (en) * | 2006-08-30 | 2008-03-06 | Merck & Co., Inc. | Topical ophthalmic formulations |
WO2008027341A2 (en) * | 2006-08-30 | 2008-03-06 | Merck & Co., Inc. | Topical ophthalmic formulations |
RU2480213C2 (ru) | 2006-10-20 | 2013-04-27 | Чилдрен'З Медикал Сентер Корпорейшн | Способ стимуляции регенерации тканей |
CN101168514B (zh) * | 2006-10-26 | 2011-12-07 | 上海药明康德新药开发有限公司 | 光学活性α-氨基辛二酸酯和α-氨基辛二酸单酯的合成方法 |
CA2672631A1 (en) | 2006-12-15 | 2008-06-19 | Glaxo Group Limited | Benzamide derivatives as ep4 receptor agonists |
GB2446652A (en) * | 2007-02-16 | 2008-08-20 | Inion Ltd | Osteogenic compounds |
KR20100016299A (ko) | 2007-05-08 | 2010-02-12 | 고쿠리츠다이가쿠호진 하마마츠이카다이가쿠 | Ep4 아고니스트를 함유하여 이루어지는 세포 상해성 t 세포의 활성화제 |
TW200911245A (en) * | 2007-06-07 | 2009-03-16 | Astellas Pharma Inc | Pyridone derivatives |
GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
CN101468985A (zh) * | 2007-12-28 | 2009-07-01 | 中国人民解放军军事医学科学院毒物药物研究所 | 5-(3-芳杂环取代苯基)四氮唑类化合物及其抗hiv/aids的应用 |
US8633310B2 (en) | 2008-02-19 | 2014-01-21 | Allergan, Inc. | Therapeutic substituted lactams |
US7964596B2 (en) | 2008-03-07 | 2011-06-21 | Allergan, Inc. | Therapeutic compounds |
US20120190637A1 (en) | 2009-10-14 | 2012-07-26 | Gemmus Pharma, Inc. | Combination therapy treatment for viral infections |
CA2738045C (en) * | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
NZ717739A (en) | 2013-08-09 | 2023-12-22 | Ardelyx Inc | Compounds and methods for inhibiting phosphate transport |
US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
EP3307747A4 (en) | 2015-06-12 | 2019-02-27 | Simon Fraser University | AMIDE-LINKED EP4-BISPHOSPHONATE AGONIST COMPOUNDS AND USES THEREOF |
WO2017126635A1 (ja) * | 2016-01-22 | 2017-07-27 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
BR112020012405A2 (pt) | 2017-12-25 | 2020-11-24 | Asahi Kasei Pharma Corporation | composto cíclico de 6 membros contendo nitrogênio. |
US20200368223A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Methods for inhibiting phosphate transport |
CN111269193B (zh) * | 2020-04-02 | 2022-05-24 | 湖南海利常德农药化工有限公司 | 一种苯并[e][1,3]噁嗪-2,4-二酮的制备方法 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1524818A (en) | 1974-11-29 | 1978-09-13 | Beecham Group Ltd | 12-azaprostaglandins |
US4177346A (en) | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
EP0008186A1 (en) | 1978-08-08 | 1980-02-20 | Beecham Group Plc | Cyclic diamides, a process for their preparation and their pharmaceutical compositions |
FR2534580A1 (fr) | 1982-10-13 | 1984-04-20 | Synthelabo | Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent |
US5151444B1 (en) | 1987-09-18 | 1999-07-06 | R Tech Ueno Ltd | Ocular hypotensive agents |
US4960771A (en) * | 1988-07-12 | 1990-10-02 | Rajadhyaksha Vithal J | Oxazolidinone penetration enhancing compounds |
US5296504A (en) | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
ES2317964T5 (es) | 1988-09-06 | 2015-02-20 | Pfizer Health Ab | Derivado de prostaglandina-F2alfa para el tratamiento de glaucoma o hipertensión ocular |
US5352708A (en) | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5922773A (en) | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
US5510383A (en) | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
JPH10265454A (ja) | 1997-01-27 | 1998-10-06 | Ono Pharmaceut Co Ltd | 3,7−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
US6043275A (en) | 1998-04-16 | 2000-03-28 | Ono Pharmaceutical Co., Ltd. | 3,7-dithiaprostanoic acid derivative |
US6586468B1 (en) | 1998-09-14 | 2003-07-01 | Ono Pharmaceutical Co., Ltd. | ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient |
JP2002527400A (ja) | 1998-10-15 | 2002-08-27 | メルク エンド カムパニー インコーポレーテッド | 骨形成刺激方法 |
AU2183900A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
TR200201643T2 (tr) | 1999-12-22 | 2002-11-21 | Pfizer Products Inc. | Osteoporoz tedavisi için EP4 reseptörünü seçici agonistler. |
PL358481A1 (en) | 2000-03-17 | 2004-08-09 | Alcon Inc. | 6-hydroxy-indazole derivatives for treating glaucoma |
CA2374731A1 (en) | 2000-03-31 | 2001-10-04 | Toray Industries, Inc. | Agent for modulating growth or generation of hair |
AU2001290250A1 (en) | 2000-09-21 | 2002-04-02 | Ono Pharmaceutical Co. Ltd. | Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
NZ525164A (en) | 2000-11-27 | 2005-04-29 | Pfizer Prod Inc | EP4 receptor selective agonists in the treatment of osteoporosis |
CA2434495A1 (en) | 2001-01-30 | 2002-08-08 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
JP2005502318A (ja) | 2001-03-22 | 2005-01-27 | メルク エンド カムパニー インコーポレーテッド | Mch1r欠損マウス |
JP2005519879A (ja) | 2001-12-03 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | Ep4受容体作動剤とその組成物および方法 |
WO2003047513A2 (en) | 2001-12-03 | 2003-06-12 | Merck & Co., Inc. | Method for treating ocular hypertension |
US20050256117A1 (en) | 2002-06-14 | 2005-11-17 | Meng Hsin Chen | Ophthalmic compositions for treating ocular hypertension |
US20050239787A1 (en) | 2002-06-17 | 2005-10-27 | Goetz Michael A | Novel maxi-k channel blockers, methods of use and process for making the same |
JP2005533055A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | 新規マキシkチャンネルブロッカー、その使用方法および製造方法 |
US7053085B2 (en) * | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
CA2511255C (en) | 2003-01-10 | 2009-04-07 | F. Hoffmann-La Roche Ag | 2-piperidone derivatives as prostaglandin agonists |
US6747037B1 (en) | 2003-06-06 | 2004-06-08 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
-
2004
- 2004-03-10 US US10/797,257 patent/US7053085B2/en not_active Ceased
- 2004-03-24 PE PE2004000303A patent/PE20050522A1/es not_active Application Discontinuation
- 2004-03-24 AR AR20040100984A patent/AR040806A1/es not_active Application Discontinuation
- 2004-03-25 TW TW093108108A patent/TW200427670A/zh unknown
- 2004-03-26 AT AT04723484T patent/ATE474837T1/de not_active IP Right Cessation
- 2004-03-26 ES ES04723484T patent/ES2347434T3/es not_active Expired - Lifetime
- 2004-03-26 BR BRPI0408690-2A patent/BRPI0408690A/pt not_active Application Discontinuation
- 2004-03-26 WO PCT/CA2004/000471 patent/WO2004085431A1/en active Application Filing
- 2004-03-26 MX MXPA05010189A patent/MXPA05010189A/es unknown
- 2004-03-26 CN CNA200480008186XA patent/CN1764659A/zh active Pending
- 2004-03-26 KR KR1020057018107A patent/KR20060002873A/ko not_active Application Discontinuation
- 2004-03-26 DE DE602004028229T patent/DE602004028229D1/de not_active Expired - Lifetime
- 2004-03-26 JP JP2006504090A patent/JP4866992B2/ja not_active Expired - Lifetime
- 2004-03-26 CA CA2519938A patent/CA2519938C/en not_active Expired - Lifetime
- 2004-03-26 WO PCT/CA2004/000470 patent/WO2004085430A1/en active Application Filing
- 2004-03-26 EP EP04723484A patent/EP1613621B1/en not_active Expired - Lifetime
- 2004-03-26 CL CL200400655A patent/CL2004000655A1/es unknown
- 2004-03-26 RU RU2005132930/04A patent/RU2005132930A/ru not_active Application Discontinuation
-
2005
- 2005-06-07 US US11/146,992 patent/US7238710B2/en not_active Expired - Lifetime
- 2005-08-25 IS IS7999A patent/IS7999A/is unknown
- 2005-09-14 MA MA28497A patent/MA27667A1/fr unknown
- 2005-09-23 EC EC2005006037A patent/ECSP056037A/es unknown
- 2005-09-23 HR HR20050845A patent/HRP20050845A2/xx not_active Application Discontinuation
- 2005-10-25 NO NO20054951A patent/NO20054951L/no unknown
-
2007
- 2007-04-26 US US11/796,044 patent/USRE42562E1/en active Active
-
2011
- 2011-06-03 US US13/152,586 patent/US20110237511A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2519938C (en) | 2010-11-30 |
BRPI0408690A (pt) | 2006-03-28 |
ES2347434T3 (es) | 2010-10-29 |
MA27667A1 (fr) | 2005-12-01 |
DE602004028229D1 (de) | 2010-09-02 |
USRE42562E1 (en) | 2011-07-19 |
US20050227969A1 (en) | 2005-10-13 |
US20040198701A1 (en) | 2004-10-07 |
US7053085B2 (en) | 2006-05-30 |
IS7999A (is) | 2005-08-25 |
ECSP056037A (es) | 2006-01-27 |
KR20060002873A (ko) | 2006-01-09 |
TW200427670A (en) | 2004-12-16 |
CN1764659A (zh) | 2006-04-26 |
EP1613621A1 (en) | 2006-01-11 |
MXPA05010189A (es) | 2006-02-22 |
NO20054951L (no) | 2005-12-22 |
JP2006520758A (ja) | 2006-09-14 |
WO2004085430A1 (en) | 2004-10-07 |
WO2004085431A1 (en) | 2004-10-07 |
JP4866992B2 (ja) | 2012-02-01 |
CA2519938A1 (en) | 2004-10-07 |
EP1613621B1 (en) | 2010-07-21 |
AR040806A1 (es) | 2005-04-20 |
HRP20050845A2 (en) | 2006-05-31 |
PE20050522A1 (es) | 2005-07-06 |
US20110237511A1 (en) | 2011-09-29 |
AU2004224261A1 (en) | 2004-10-07 |
RU2005132930A (ru) | 2006-02-10 |
CL2004000655A1 (es) | 2005-01-21 |
ATE474837T1 (de) | 2010-08-15 |
US7238710B2 (en) | 2007-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054951D0 (no) | Prostaglandinanaloger som EP4-reseptorantagonister | |
DK1562595T3 (da) | Diarylethere som opioidreceptorantagonister | |
LTPA2017005I1 (lt) | Nauji junginiai, kaip opioido receptoriaus moduliatoriai | |
DK1501809T3 (da) | Trizolderivater som tachykininreceptorantagonister | |
CY2017032I2 (el) | Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2 | |
MA28841B1 (fr) | Analogues tetrapeptidiques | |
NO20052739D0 (no) | CCR5-antagonister som medikamenter | |
DK1761519T3 (da) | Indolderivater som histaminreceptorantagonister | |
DK1723114T3 (da) | Biphenyl-forbindelser der er egnede som muskarinreceptorantagonister | |
DK1833791T3 (da) | 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister | |
DK1904477T3 (da) | Indol-3-carbonyl-spiro-piperodom-derivater som V1A-receptorantagonister | |
DE602005004011D1 (de) | Hydroisoindolin-tachykininrezeptorantagonisten | |
NO20052797D0 (no) | Fenyl eller heteroaryl aminoalkanderivater som IP-reseptorantagonister | |
SG156653A1 (en) | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | |
NO20044654L (no) | Piperidinoylpiperidiner som 5-HTIF-agonister | |
DK1943242T3 (da) | Piperidin-4-yl-pyridazin-3-ylamin-derivater som hurtigt opløsende antagonister af dopamin-2-receptorer | |
DK1660090T3 (da) | Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer | |
IL184816A0 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
DK1809624T3 (da) | Pyrimidinsulfonamidderivater som kemokinreceptor-modulatorer | |
DK1928821T3 (da) | Carboxamidderivater som muscarinreceptorantagonister | |
DK1758886T3 (da) | Piperazindioner som oxytocinreceptor-antagonister | |
DK1778243T3 (da) | Substituerede azepinderivater som serotoninreceptormodulatorer | |
IS7874A (is) | Ímídasókínólínafleiður sem adenósín A3 viðtakabindlar | |
DK1648882T3 (da) | 3-fluor-piperidiner som NMDA/NR2B-antagonister | |
DK1912976T3 (da) | Indol-3-YL-carbonyl-piperidin-benzoimidazolderivater som V1A-receptorantagonister |